Fortrea Holdings Inc. (NASDAQ:FTRE - Get Free Report) traded down 3.9% during mid-day trading on Monday . The stock traded as low as $5.63 and last traded at $5.68. 350,400 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,863,620 shares. The stock had previously closed at $5.91.
Wall Street Analyst Weigh In
Several research analysts have weighed in on FTRE shares. William Blair restated a "market perform" rating on shares of Fortrea in a report on Tuesday, March 4th. Robert W. Baird set a $12.00 price target on Fortrea in a report on Tuesday, March 4th. Cowen restated a "hold" rating on shares of Fortrea in a research note on Wednesday, May 14th. Mizuho reduced their target price on shares of Fortrea from $10.00 to $8.00 and set a "neutral" rating for the company in a research note on Wednesday, May 14th. Finally, Truist Financial assumed coverage on shares of Fortrea in a research report on Friday, May 2nd. They set a "hold" rating and a $7.00 price target on the stock. Two analysts have rated the stock with a sell rating and twelve have given a hold rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $15.00.
Get Our Latest Stock Analysis on Fortrea
Fortrea Price Performance
The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.18. The firm has a market capitalization of $524.00 million, a PE ratio of -1.69, a price-to-earnings-growth ratio of 1.78 and a beta of 1.59. The business's 50 day moving average is $5.25 and its two-hundred day moving average is $11.78.
Fortrea (NASDAQ:FTRE - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.09. The company had revenue of $651.30 million during the quarter, compared to analyst estimates of $609.63 million. Fortrea had a positive return on equity of 2.00% and a negative net margin of 10.99%. Equities research analysts anticipate that Fortrea Holdings Inc. will post 0.51 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Fortrea
Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC increased its stake in Fortrea by 21.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 11,073 shares of the company's stock valued at $207,000 after acquiring an additional 1,986 shares during the last quarter. Rhumbline Advisers increased its position in shares of Fortrea by 1.8% during the 4th quarter. Rhumbline Advisers now owns 234,539 shares of the company's stock valued at $4,374,000 after purchasing an additional 4,064 shares during the last quarter. Principal Financial Group Inc. raised its holdings in shares of Fortrea by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 434,953 shares of the company's stock valued at $8,112,000 after buying an additional 13,026 shares in the last quarter. Peregrine Capital Management LLC purchased a new position in shares of Fortrea during the 4th quarter valued at about $5,627,000. Finally, Hahn Capital Management LLC lifted its position in Fortrea by 47.6% in the 4th quarter. Hahn Capital Management LLC now owns 38,720 shares of the company's stock worth $722,000 after buying an additional 12,495 shares during the last quarter.
About Fortrea
(
Get Free Report)
Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Fortrea, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fortrea wasn't on the list.
While Fortrea currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
